Karyopharm Therapeutics Grants Restricted Stock Units to New Employee under Nasdaq Rule 5635(c)(4)

Karyopharm Therapeutics Grants Inducement Awards

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leading pharmaceutical firm dedicated to developing innovative cancer treatments, has announced significant inducement grants under the Nasdaq Listing Rule 5635(c)(4). As of July 31, 2025, the company granted 333 restricted stock units (RSUs) to a newly-hired employee, aimed at enhancing talent acquisition in the competitive pharmaceutical landscape.

This grant was made in accordance with Karyopharm's 2022 Inducement Stock Incentive Plan, amended to attract valuable personnel essential for the company's growth. The RSUs will vest over a three-year period, with one-third of the shares becoming accessible to the employee each year on the anniversary of the grant date. This structure encourages employee retention and performance, ensuring that the individual remains engaged with the firm during this vital period of development.

Additionally, these RSUs contain provisions for immediate vesting if a 'change in control' occurs within the first year and the employee's contract is terminated for “good reason” or without “cause.” Such measures reflect Karyopharm's commitment to protecting its workforce and ensuring that employees who contribute to the company's success are rewarded appropriately.

About Karyopharm Therapeutics

Karyopharm Therapeutics specializes in pioneering novel cancer therapies, underscoring its commitment to transforming the future of cancer treatment. Their flagship product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor, successfully approved in the United States for several oncology indications. Additionally, Karyopharm is expanding globally, with XPOVIO® also marketed in various international markets, such as NEXPOVIO® in Europe and the UK, as well as in China.

The company's strategic pipeline targets multiple cancer types, including high unmet needs in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma. Karyopharm continues to push the boundaries of pharmaceutical innovation and maintains a strong focus on the health and well-being of cancer patients.

To learn more about their cutting-edge therapies and pipeline, Karyopharm invites interested parties to visit their website at www.karyopharm.com and follow their updates on LinkedIn and X at @Karyopharm.

Overall, this recent RSU grant not only reflects Karyopharm's strategic efforts to build a robust leadership team but also aligns with their mission of enhancing patient outcomes through advanced cancer therapies. As they continue to attract top tier talent, the outlook for Karyopharm remains bright, promising growth and further innovation in cancer treatment.